Organization | Academic Medical Organization of Southwestern Ontario

Academic Medical Organization of Southwestern Ontario Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Canada

Organization Overview

First Clinical Trial

2012

NCT01843166

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Academic Medical Organization of Southwestern Ontario

Active Ingredients

Drugs in Phase 4 Trials (5)

calcium (1 trial)

denosumab (prolia) (1 trial)

etanercept (enbrel) (1 trial)

tofacitinib (xeljanz) (1 trial)

vitamin d (1 trial)

Drugs in Phase 3 Trials (2)

bisacodyl (Halflytely) (1 trial)

polyethylene glycol (1 trial)

Drugs in Phase 2 Trials (4)

amino acids (Freamine) (1 trial)

crystalloid (1 trial)

docetaxel (taxotere) (1 trial)

nedaplatin (1 trial)

Drugs in Phase 1 Trials (1)

human fecal microbiota (Reybota) (1 trial)

Drugs in Other Trials (1)

conjugated equine estrogens (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Carcinoma (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Malnutrition (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 13